[THE INVESTOR] On Oct. 17, DaihanPharm (023910) rose 3.02% to 30,700 won (US$26.91). It had increased 5.32% through the past month. Standard deviation, which indicates variableness, records 2.1% on the same period of time over one month.

Compared with its close competitors within the same industry, KOSDAQ, the monthly earnings rate of DaihanPharm was the highest, but its volatility within 1 month was relatively lower than that of its peer group's. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was 2.5. With low volatility, a satisfactory stock price lead the return-on-risk to a high level. Moreover, compared with the KOSDAQ industry, the return-on-risk is much better than the industrial mean, 1.5, and thus the industrial comparison performance was good.

On Oct. 16, institutions bought 4,136 shares, while foreigners sold 1,092 shares. As a shareholding sum by investor group for the past 4 weeks, foreigners have bought 42,736 shares with a maintenance of shareholding and individuals have bought 24,913 shares with an increasing position. However, during the same period, institutions have sold 67,649 shares with a selling trend.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.